Clinic
Mizell Memorial Hospital, INC.
Mizell Memorial Hospital, INC. was paid $1.54M by Medicaid between Jan 2018 and Nov 2024, across 74 billing codes. Its largest line is 99284, emergency room visit (serious) — 36% of everything it billed.
33Billing provider infoMIZELL MEMORIAL HOSPITAL, INC.
OPP, AL 36467
OPP, AL 36467
33aNPI1013937705assigned 07/19/2006
33bProvider typeLithotripsy Clinic/Center
28Total paid$1.54M
24GClaims79,176
24DCodes billed74
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,088 | $127K | |
| 2019 | 8,421 | $237K | |
| 2020 | 9,580 | $155K | |
| 2021 | 11,794 | $259K | |
| 2022 | 15,097 | $276K | |
| 2023 | 15,499 | $294K | |
| 2024incomplete | 10,697 | $191K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 36% | 12,375 | 8,307 | $553K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 9,682 | 7,608 | $293K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 1,930 | 1,307 | $258K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.0% | 4,403 | 3,098 | $76K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.2% | 7,849 | 5,290 | $50K |
| 80053 | Comprehensive metabolic panel | 3.0% | 6,181 | 4,331 | $46K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.6% | 3,334 | 2,604 | $41K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.6% | 4,043 | 3,019 | $40K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.0% | 2,362 | 1,943 | $31K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 779 | 696 | $27K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 310 | 214 | $16K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 499 | 429 | $15K |
62 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 772 | $8K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 110 | $8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 165 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,094 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 934 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,068 | $6K |
| 81001 | <1% | 2,427 | $6K | |
| 82553 | <1% | 540 | $4K | |
| 80306 | <1% | 561 | $4K | |
| 83735 | <1% | 883 | $4K | |
| 82550 | <1% | 772 | $3K | |
| 84484 | <1% | 543 | $3K | |
| 85027 | <1% | 759 | $3K | |
| 83880 | <1% | 178 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 206 | $2K |
| 87807 | <1% | 192 | $2K | |
| 83690 | <1% | 388 | $2K | |
| 81025 | <1% | 729 | $2K | |
| 82607 | <1% | 116 | $1K | |
| 85610 | <1% | 434 | $1K | |
| 82150 | <1% | 181 | $935.01 | |
| 81003 | <1% | 336 | $743.97 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 466 | $734.60 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 94 | $638.37 |
| 82746 | <1% | 72 | $610.88 | |
| 85730 | <1% | 433 | $518.03 | |
| 80061 | Lipid panel | <1% | 30 | $506.66 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 33 | $480.33 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 325 | $372.84 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 49 | $357.69 |
| 87186 | <1% | 57 | $303.30 | |
| 87077 | <1% | 61 | $269.40 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,000 | $235.77 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 22 | $227.92 |
| 86140 | <1% | 118 | $220.69 | |
| 83550 | <1% | 16 | $170.94 | |
| 83605 | <1% | 15 | $162.80 | |
| 82728 | <1% | 16 | $162.80 | |
| 83540 | <1% | 16 | $112.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 731 | $87.48 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,898 | $53.80 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 188 | $9.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 438 | $6.30 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 101 | $4.29 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,332 | $2.60 |
| 36591 | 0% | 163 | $0.00 | |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 494 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 195 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 20 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 123 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 82 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 90 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 14 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 1,276 | $0.00 |
| 99307 | 0% | 197 | $0.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 649 | $0.00 |
| 73110 | 0% | 19 | $0.00 | |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | 0% | 127 | $0.00 |
| X1574 | 0% | 19 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 30 | $0.00 |
| 85007 | 0% | 13 | $0.00 | |
| 73610 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWYATT, JANA (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Mizell Memorial Hospital, INC. | Opp, AL | $633K |
| Mizell Memorial Hospital, INC. | Opp, AL | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.